Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>Context Therapeutics’ FY21 results echoed previously highlighted progress on its novel women’s oncology franchise. With all four clinical programs expected to have initial read-outs in 2022, the next few months could be instrumental in shaping the outlook for the company. The share price, which has remained range bound in recent months, could potentially see an uplift on positive data readouts. Importantly, the cash position remains robust with the year-end cash balance of $50m sufficient to extend the runway into 2024. In the nearer term, we expect the upcoming presentations at the AACR (April 2022) to likely catalyze a momentum shift, contingent on the quality of the data. Pending upcoming read-outs, our valuation remains largely unchanged at $134.1m or $8.40/share.</p>

Context Therapeutics’ FY21 results echoed previously highlighted progress on its novel women’s oncology franchise. With all four clinical programs expected to have initial read-outs in 2022, the next few months could be instrumental in shaping the outlook for the company. The share price, which has remained range bound in recent months, could potentially see an uplift on positive data readouts. Importantly, the cash position remains robust with the year-end cash balance of $50m sufficient to extend the runway into 2024. In the nearer term, we expect the upcoming presentations at the AACR (April 2022) to likely catalyze a momentum shift, contingent on the quality of the data. Pending upcoming read-outs, our valuation remains largely unchanged at $134.1m or $8.40/share.

Context Therapeutics - A catalyst-rich year ahead

<p>Context Therapeutics is a Nasdaq-listed biopharma company developing novel therapeutics focused on women’s oncology indications. Lead program onapristone extended release (ONA-XR) is a potential first-in-class progesterone receptor (PR) antagonist being evaluated in several mid-stage clinical programs in advanced breast, endometrial and ovarian cancer, all areas with significant unmet need. In-licensing a bi-specific monoclonal antibody, CLDN6Xcd3, in April 2021 has added another (preclinical) novel compound to the pipeline. With multiple data readouts expected in 2022, we foresee several inflection points in the coming months. We initiate coverage with a valuation of $134.9m or $8.45/share.</p>

Context Therapeutics is a Nasdaq-listed biopharma company developing novel therapeutics focused on women’s oncology indications. Lead program onapristone extended release (ONA-XR) is a potential first-in-class progesterone receptor (PR) antagonist being evaluated in several mid-stage clinical programs in advanced breast, endometrial and ovarian cancer, all areas with significant unmet need. In-licensing a bi-specific monoclonal antibody, CLDN6Xcd3, in April 2021 has added another (preclinical) novel compound to the pipeline. With multiple data readouts expected in 2022, we foresee several inflection points in the coming months. We initiate coverage with a valuation of $134.9m or $8.45/share.

Context Therapeutics - Women’s oncology play with a novel pipeline

United States

Context Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on development of medicines and novel therapies for the treatment of female cancer patients. Context Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Context Therapeutics (CNTX US)

Context Therapeutics - A catalyst-rich year ahead

Context Therapeutics’ FY21 results echoed previously highlighted progress on its novel women’s oncology franchise. With all four clinical programs...

Edison Investment Research

Context Therapeutics - Women’s oncology play with a novel pipeline

Context Therapeutics is a Nasdaq-listed biopharma company developing novel therapeutics focused on women’s oncology indications. Lead program...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)